权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)

2/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系（教育核心）

基本信息

批准号：
10249137
负责人：
Maurizio Pellecchia
金额：
$ 2.82万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10249137
关键词：
African American American Antineoplastic Agents Applications Grants Award Basic Science Bioinformatics Biology California City of Hope Comprehensive Cancer Center Clinical Clinical Trials Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Drug Design Drug Targeting Eating Education Education and Outreach Educational Curriculum Engineering Ethics European Exposure to Faculty Funding Goals Health Sciences Hispanic Americans Hispanic-serving Institution Inequality Institution Investments Joints Laboratories Latino Master&apos s Degree Medical Students Mentorship Methods NCI Center for Cancer Research Participant Patients Persons Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Physicians Precision Medicine Initiative Reporting Research Research Infrastructure Research Personnel Resources Rotation Running Scientist Societies Students System Testing Therapeutic Clinical Trial Training Training Programs Translating United States United States Food and Drug Administration United States National Institutes of Health Universities Visit anticancer research cancer health disparity career chimeric antigen receptor T cells clinical translation community clinic community partnership curriculum development disparity elimination diversity and equity diversity and inclusion drug development drug discovery drug repurposing education research education resources ethnic diversity experience first-in-human graduate student health disparity innovation manufacturing facility medical schools minority communities nanotherapy news next generation novel therapeutics outreach precision drugs precision medicine programs research and development screening social determinants stem cell therapy success summer research targeted agent undergraduate student virtual

项目摘要

Abstract: University of California at Riverside (UCR) is the newest medical school in the University of California system and a NIH-designated ISUPS institution. UCR's mandate is to serve SoCal's majority-minority communities and train the next generation of Latino/Hispanic-American and Black/African-American engineers, biologists, and physicians. City of Hope Comprehensive Cancer Center (CoH-CCC) is a Comprehensive Cancer Center whose 121 researchers have been awarded over $75M in NIH/NCI funding. CoH-CCC leads the world in academic drug discovery and has commercialized blockbusters drugs such as HumalinTM, HerceptinTM, and RituximabTM. CoH has world-class bioinformatics for drug design, extensive screening and synthetic capability, three onsite GMP-manufacturing facilities, and a robust clinical/translation Phase I program. Over the past 5 years 21 drugs have gone from R01 concept to first-in-man testing. The goal of the Collaborative Cancer Research Education Program (C-REP) is for UCR and CoH-CCC to develop the research experiences, curriculum, and outreach education resources necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. Aim 1: Research Experiences will provide tailored research experiences in cancer research and drug development. Aim 2: Curriculum Development will provide courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. Aim 3 Outreach Education and Resources will 1) expose early stage investigators to career opportunities drug development and clinical trials and 2) provide training and capacity building for fellows and faculty to translate their findings to drive drug discovery.

摘要：加州大学河滨分校(UCR)是加州大学系统中最新的医学院以及美国国立卫生研究院指定的ISUPS机构。UCR的使命是服务于SoCal的少数族裔社区并培养下一代拉丁裔/拉美裔美国人和黑人/非裔美国人的工程师、生物学家、还有医生。希望之城综合癌症中心(CoH-CCC)是一个综合性癌症中心其121名研究人员已获得超过7500万美元的NIH/NCI资金。COH-CCC在全球领先学术药物发现，并已将HumalinTM、HerceptinTM等重磅炸弹药物商业化利妥昔单抗TM.COH拥有世界级的药物设计生物信息学、广泛的筛选和合成能力，三个现场GMP生产设施，以及一个强大的临床/翻译第一阶段计划。在过去5年中 21年来，药物已经从R01概念试验变成了第一次人体试验。合作癌症研究教育计划(C-REP)的目标是针对UCR和CoH-CCC 发展所需的研究经验、课程和外展教育资源反映南加州内陆种族多样性的下一代治疗学研究人员。目标 1：研究经验将提供癌症研究和药物方面的量身定制的研究经验发展。目标2：课程开发将提供介绍UCR和CoH学生的课程并致力于药物开发和差异健康科学的方法和创新。目标3 外展教育和资源将使早期调查人员接触毒品的职业机会开发和临床试验；2)为研究员和教职员工提供翻译培训和能力建设他们的发现推动了药物发现。